| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536834 | Vaccine | 2017 | 10 Pages |
Abstract
GBS maternal immunization, with IAP as indicated for unvaccinated women, could be an attractive alternative to screening/IAP if a pentavalent vaccine is sufficiently effective. Coverage, typically low for maternal vaccines, is key to the vaccine's public health impact.
Keywords
group B Streptococcus (GBS)CDCABCsGBSIAPCost-effectiveness acceptability curveHCUPQALYEOGBSCEACCost-effectiveness analysis (CEA)NAATCeAnucleic acid amplification testUnited StatesMaternal immunizationCost-effectiveness analysisNeonatal sepsisQuality-adjusted life-yearCenters for Disease Control and PreventionNeonatal meningitisHealthcare Cost and Utilization ProjectIntrapartum antibiotic prophylaxisgroup B Streptococcus
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sun-Young Kim, Chi Nguyen, Louise B. Russell, Sara Tomczyk, Fatimah Abdul-Hakeem, Stephanie J. Schrag, Jennifer R. Verani, Anushua Sinha,